Nektar Therapeutics Faces Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NKTR?
Source: Globenewswire
- Shareholder Loss Assessment: Institutional investors holding Nektar Therapeutics (NASDAQ: NKTR) shares from February 26 to December 15, 2025, experienced a loss of $4.14 per share, representing a 7.77% decline, primarily due to issues disclosed on December 16, 2025, which undermined investor confidence.
- Lawsuit Background: The action, filed in the Northern District of California, alleges that Nektar and its management made false statements regarding the integrity of patient enrollment in the REZOLVE-AA trial, claiming adherence to strict protocols while including four ineligible patients, which compromised the trial's statistical significance.
- Role of Institutional Investors: Institutional investors play a critical role in securities class actions, as their participation as lead plaintiffs ensures vigorous prosecution of claims and meaningful recoveries for all affected shareholders, particularly retirement plan participants whose savings may have been impacted.
- Lead Plaintiff Opportunities: Investors must file by May 5, 2026, to be considered for lead plaintiff status, allowing them to select counsel and oversee settlement negotiations, with attorney fees covered from any recovery obtained, thus minimizing financial risk in participation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 83.220
Low
102.00
Averages
123.43
High
165.00
Current: 83.220
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements, resulting in investor losses.
- Market Reaction: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for global investors and encourages affected shareholders to take action before class certification to ensure their rights are protected.
See More
Reminder for Nektar Therapeutics Class Action Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocols in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses when the true information was disclosed.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses when the true details were revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, indicating the legal proceedings could have significant implications for the company's future stock performance and reputation.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements, resulting in investor losses.
- Market Reaction: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for global investors and encourages affected shareholders to take action before class certification to ensure their rights are protected.
See More
Reminder for Nektar Therapeutics Class Action Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocols in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses when the true information was disclosed.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses when the true details were revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, indicating the legal proceedings could have significant implications for the company's future stock performance and reputation.
See More
